Can You Get Pregnant With Asherman’s Syndrome?

Pregnancy is possible with Asherman’s syndrome, but the path typically runs through treatment first, and the odds depend heavily on how much of the uterine lining has been replaced by scar tissue. After surgical removal of adhesions, pregnancy rates in treated patients range from roughly 30% to over 50%, with milder cases faring considerably better than severe ones. The condition complicates fertility in ways that go beyond simply blocking an embryo from implanting, and even after a successful pregnancy is achieved, the risks during that pregnancy are higher than average.

What Asherman’s Syndrome Does to Fertility

Asherman’s syndrome develops when bands of scar tissue, called intrauterine adhesions, form inside the uterus. The most common trigger is a surgical scraping (curettage) of a recently pregnant uterus, though the condition can also follow other uterine surgeries, uterine artery embolization, or uterine tuberculosis.¹ These adhesions can partially or completely obliterate the uterine cavity, which creates several overlapping problems for someone trying to conceive.

The scar tissue physically blocks the space where an embryo would implant. But the damage goes deeper than architecture. Even when surgery successfully removes adhesions and restores the cavity to a normal shape, normal endometrial function is not guaranteed. Research has shown that while endometrial thickness can improve after surgical treatment, blood flow to the lining often does not recover to the same degree.² The endometrium needs adequate blood supply to thicken properly each cycle and to sustain an early pregnancy. When the deepest layer of the lining has been damaged, even a cavity that looks anatomically normal on imaging may not function well enough to support implantation or maintain a pregnancy through the critical early weeks.

This distinction between structural repair and functional recovery is one reason Asherman’s syndrome can be so frustrating. A patient might be told that her surgery went well and the adhesions are gone, yet still struggle to conceive or carry a pregnancy.

How Severity Shapes the Outlook

Not all cases of Asherman’s syndrome are equal. Mild adhesions that affect a small portion of the cavity carry a very different prognosis than severe scarring that obliterates most of it. In one study of treated patients, pregnancy rates were roughly 53% for mild disease, about 27% for moderate disease, and under 10% for severe cases.² The gap is stark. For someone with a few thin adhesions, the condition can sometimes be resolved in a single procedure with excellent fertility afterward. For someone with dense scarring throughout the cavity, the road is longer and the odds lower.

Age also plays a significant role. In a study of women with severe disease (stage 3 and 4), those aged 35 or younger conceived at about twice the rate of those over 35.³ This makes sense: ovarian reserve declines with age regardless of uterine health, so a damaged uterus combined with fewer available eggs compounds the difficulty. Younger patients with mild to moderate adhesions tend to have the most encouraging outcomes after treatment.

Multiple classification systems exist for grading the severity of intrauterine adhesions, and the lack of a single universally accepted system has made it harder to compare results across studies.⁴ Newer scoring approaches are trying to incorporate factors like endometrial thickness on ultrasound, which may give a better sense of how the lining is actually functioning rather than just how many adhesions are visible.

Surgical Treatment and What It Achieves

The standard treatment is hysteroscopic adhesiolysis, a procedure in which a thin camera is guided through the cervix and the adhesions are carefully cut away. In one large series of over 600 women treated at a specialized center, the procedure was successful in about 95% of cases, and normal menstrual flow returned in nearly 98%.⁵ A smaller series found that all patients resumed normal menstrual cycles, and more than half of the infertile patients who attempted pregnancy conceived.⁶

One persistent challenge is adhesion recurrence. In that same large centralized series, adhesions spontaneously reformed in about 27% of successfully treated cases.⁵ This means many patients need more than one surgery. Several strategies are used to try to prevent scar tissue from returning after the procedure. A comparison study found that placing an intrauterine balloon after surgery was more effective than an intrauterine device (IUD), and both were more effective than hyaluronic acid gel or no barrier at all.⁷

Does Estrogen Therapy After Surgery Help?

For years, many specialists prescribed estrogen after adhesiolysis with the reasoning that it would stimulate the endometrium to regrow and cover the raw surfaces before scarring could take hold. A systematic review found that estrogen therapy does appear beneficial, particularly when combined with other measures like intrauterine barriers, and especially in moderate to severe cases.⁸

However, a randomized trial challenged the assumption that estrogen is always necessary. Women who did not receive estrogen after surgery had comparable adhesion recurrence rates and similar pregnancy outcomes. Among those who received usual care including estrogen, about 90% became pregnant within three years and roughly 68% had a living child. In the group that skipped estrogen, those numbers were about 84% and 60%, with no statistically significant difference between the groups.⁹ These numbers are actually quite encouraging overall, and they suggest that at least for some patients, the surgery itself may matter more than the hormonal regimen that follows it. The debate isn’t settled, and most clinicians still prescribe estrogen as a precaution, but the evidence that it makes a clear difference is thinner than many patients are told.

IVF After Asherman’s Syndrome

When natural conception doesn’t happen after surgical treatment, IVF is a common next step. But the uterine damage that defines Asherman’s syndrome can undermine IVF success as well. A matched study comparing women treated for the syndrome against controls found that the overall time to achieve a live birth was significantly longer for the Asherman’s group. Moderate to severe disease was an independent factor reducing the chance of a live birth through IVF, and women who did achieve live births had thicker endometrial linings on average than those who did not.¹⁰

Endometrial thickness emerges repeatedly in the research as one of the strongest predictors of success. Patients whose lining recovers to a healthy thickness after treatment tend to have outcomes closer to the general IVF population, while those whose lining remains thin despite treatment face an uphill battle. This is consistent with the mechanism described earlier: when the deepest layer of endometrium is damaged, functional recovery lags behind structural repair, and a thin lining simply can’t sustain implantation as reliably.

Pregnancy Risks That Come After Conception

Getting pregnant is only half the challenge. Pregnancies after Asherman’s treatment carry elevated risks that both patients and their obstetricians need to plan for. In a study tracking births after hysteroscopic adhesiolysis, the miscarriage rate was about 23%, abnormal placentation occurred in roughly 18% of live births, and premature delivery affected about 29%.¹¹

A propensity-matched cohort study confirmed that premature delivery was significantly more common among women with Asherman’s syndrome compared to controls, though reassuringly, rates of growth restriction and poor neonatal outcomes were not elevated. Having had two or more curettages before Asherman’s treatment, or needing multiple hysteroscopic procedures, increased the risk of complications like abnormally invasive placenta and retained placenta.¹²

Placenta Accreta and Related Complications

One complication that deserves its own discussion is placenta accreta spectrum, a condition where the placenta grows too deeply into the uterine wall. This is particularly relevant for Asherman’s patients because the same endometrial damage that caused the adhesions also leaves the uterine wall vulnerable to abnormal placental invasion.

Estimates of how often this happens vary widely. An older review found the rate of placenta accreta in Asherman’s patients at roughly 13-14%, while another reported adherent placenta causing postpartum hemorrhage in about 12.5% of patients after adhesiolysis.¹³ A literature review pooling data across 12 studies found a lower rate of about 2.6% for confirmed placenta accreta, though it noted that broader placental problems including retained placenta and postpartum hemorrhage affected a much larger share of patients.¹⁴

A more recent single-center study found a strikingly higher rate: about 24% of pregnancies after Asherman’s treatment involved placenta accreta spectrum. A history of cesarean delivery was the strongest risk factor, roughly quadrupling the odds. Among those with placenta accreta spectrum, about 39% required cesarean hysterectomy, meaning the uterus had to be removed at delivery.¹⁵ These pregnancies need close monitoring, and delivery planning at a hospital with the right surgical resources is important. Patients and their providers should discuss placental screening during routine prenatal care, as prenatal diagnosis of accreta allows for safer delivery planning.

Monitoring During Pregnancy

Pregnancies after Asherman’s treatment are generally treated as high risk. Patients should be monitored for cervical weakness, which can lead to miscarriage or very early delivery, as well as for abnormal placentation.¹⁶ Ultrasound assessments of placental location and invasion are particularly important given the elevated rates of accreta spectrum described above. Preterm labor is also a concern, so standard surveillance for signs of early cervical shortening or contractions is part of standard care for these patients.

When the Uterus Cannot Be Repaired

For women with severe or refractory Asherman’s syndrome where the uterine lining cannot be restored to functional status despite repeated surgeries, gestational surrogacy becomes an option. The patient’s own eggs can often be used, since the ovaries are unaffected by intrauterine adhesions, but the embryo is carried by another person. One large surrogacy program reported a pregnancy rate of about 54% per cycle for the group of patients who “cannot carry,” which included women with severe Asherman’s syndrome alongside those with other uterine conditions.¹⁷ Surrogacy carries its own legal, financial, and emotional complexities, but it does offer a pathway to a genetically related child for patients whose own uterus is no longer viable.

Experimental Therapies on the Horizon

The frustrating cases of Asherman’s syndrome are those where the endometrium simply won’t regenerate, no matter how many times adhesions are removed. This has driven considerable interest in regenerative approaches, particularly stem cell therapy. The broad idea is to introduce cells that can help rebuild the functional lining from the inside.

A review of clinical trials found that various types of stem cells, including those derived from menstrual blood, bone marrow, umbilical cord tissue, and fat tissue, have shown improved outcomes in both menstrual restoration and fertility in early studies of human patients.¹⁸ A phase 1/2 trial using bone marrow-derived CD133+ stem cells in 20 women with moderate to severe Asherman’s syndrome who had failed previous surgeries found the therapy safe and well tolerated, with no treatment-related serious adverse events.¹⁹ This therapy has already received orphan drug designation from both European and American drug regulators, signaling that it is being taken seriously as a potential treatment for a condition with limited options.

By contrast, platelet-rich plasma, which has been hyped for various regenerative applications, did not show a significant benefit for Asherman’s patients in a randomized trial. Neither menstrual pattern, bleeding duration, nor adhesion staging improved compared to the control group.²⁰ Patients offered PRP as an Asherman’s treatment should be aware that the current evidence does not support its effectiveness.

The Psychological Weight of Treatment

Something that rarely gets discussed in clinical summaries is how emotionally devastating this condition can be. A recent study of non-pregnant women with Asherman’s syndrome found that about 42% met criteria for clinical anxiety, 38% reported significant hostility, and over half reported reduced vitality. Women who had been in treatment for more than two years had a 16-fold higher risk of anxiety, and those who had undergone six or more hysteroscopies had a 14-fold higher risk of cognitive problems like difficulty concentrating.²¹

These numbers reflect something patients already know: the cycle of surgery, waiting, re-adhesion, and repeat surgery is grueling. Each procedure carries hope that this time it will work, and each recurrence feels like starting over. The condition also tends to be poorly recognized by general gynecologists, meaning many patients go through an extended period of dismissed symptoms before receiving a correct diagnosis. The combination of diagnostic delay, repeated procedures, uncertain prognosis, and the deeply personal nature of fertility creates a psychological burden that clinicians are only now beginning to measure. For patients going through this, seeking psychological support is not a luxury but a practical step that can affect treatment adherence and recovery.

Tuberculosis as a Distinct and Difficult Cause

In regions where genital tuberculosis is common, particularly parts of South Asia and sub-Saharan Africa, the cause of Asherman’s syndrome matters for prognosis in a way that doesn’t apply to other patients. Tuberculosis tends to destroy the deepest regenerative layer of the endometrium, meaning that even successful surgical removal of adhesions often fails to restore a functioning lining. Studies have confirmed that blood flow in the tissue beneath the endometrium remains poor in these patients even when the endometrial thickness appears adequate on ultrasound.² For women whose Asherman’s syndrome was caused by tuberculosis, treatment outcomes are generally worse, and surrogacy or adoption may need to be discussed earlier in the treatment process rather than after multiple failed surgical attempts.

1
PubMed Central. Asherman’s syndrome: current perspectives on diagnosis and management
2
PubMed Central. Reproductive Outcome of Patients with Asherman’s Syndrome: A SAIMS Experience
3
PubMed. Fertility after treatment of Asherman’s syndrome stage 3 and 4
4
PubMed Central. A New Intrauterine Adhesions Classification System: The “Loddo Score”
5
PubMed. Results of centralized Asherman surgery, 2003-2013
6
PubMed Central. Hysteroscopic adhesiolysis for patients with Asherman’s syndrome: menstrual and fertility outcomes
7
PubMed. A comparison of intrauterine balloon, intrauterine contraceptive device and hyaluronic acid gel in the prevention of adhesion reformation following hysteroscopic surgery for Asherman syndrome: a cohort study
8
PubMed. Efficacy of estrogen therapy in patients with intrauterine adhesions: systematic review
9
PubMed Central. Hormonal support in women with Asherman syndrome does not lead to better outcomes: A randomized trial
10
PubMed. Reproductive Outcomes and Overall Prognosis of Women with Asherman’s Syndrome Undergoing IVF
11
Human Reproduction. Live birth rate and obstetric complications following the hysteroscopic management of intrauterine adhesions including Asherman syndrome
12
Human Reproduction. The perinatal outcomes of women treated for Asherman syndrome: a propensity score-matched cohort study
13
PubMed Central. Placenta accreta: adherent placenta due to Asherman syndrome
14
PubMed Central. Placenta Accreta following Hysteroscopic Lysis of Adhesions Caused by Asherman’s Syndrome: A Case Report and Literature Review
15
PubMed. Incidence and Clinical Implications of Placenta Accreta Spectrum after Treatment for Asherman Syndrome
16
Reproductive BioMedicine Online. Can You Get Pregnant With Asherman’s Syndrome?
17
Human Reproduction. Assisted reproduction involving gestational surrogacy: an analysis of the medical, psychosocial and legal issues: experience from a large surrogacy program
18
PubMed Central. An update on stem cell therapy for Asherman syndrome
19
Nature Communications. Autologous cell therapy with CD133+ bone marrow-derived stem cells for Asherman Syndrome: a phase 1/2 trial
20
PubMed Central. Platelet-rich plasma in the management of Asherman’s syndrome: An RCT
21
PubMed. In the Shadow of Adhesions: Risk Factors and Mental Health in Asherman Syndrome